Business
Ondine receives impact award at IPA World Congress
Ondine receives impact award at IPA World Congress.
About this update from Ondine Biomedical, Inc.
[{"type":"text","content":"\n\nNon-regulatory announcement\n \n17 July 2023\n \nONDINE BIOMEDICAL INC. \n(\"Ondine Biomedical\", \"Ondine\" or the \"Company\") \nOndine receives impact award at IPA World Congress\nOndine Biomedical is recipient of the TAYYABA HASAN IMPACT AWARD at 18th IPA World Congress, Finland\nOndine Biomedical (LON:OBI) was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Tampere, Finland, for demonstrating exceptional perseverance and clinical acumen. Ondine has demonstrated successful outcomes in a number of key studies for both prevention and treatment against strains of SARS-CoV-2 including deployment in large scale enterprises.\nThe IPA promotes the benefits of light-activated therapies to treat infections that pose the biggest threats to global health security. The IPA World Congress featured research on a number of areas that use light-activated photosensitizers, including photodynamic therapy (PDT), antimicrobial photodisinfection, photoimmunotherapy (PIT), photodiagnosis (PD), etc.\nNewly elected President of the IPA Board of Directors, Colin Hopper of UCL, commented, \"The international Congress recognizes leaders from around the world, in their respective fields, for their contributions that continue to advance the field of photomedicine. The IPA wishes to congratulate the Ondine team for being recognized as the 2023 recipient of the Tayyaba Hasan IMPACT Award.\n\"This Team Award recognizes the collective efforts and successes in advancing the clinical safety and efficacy of Photodynamic Therapy for antiviral applications during the COVID-19 pandemic. The outcomes of this work and these studies will help to serve future pandemic preparedness and support the ongoing efforts for advanced antimicrobial resistance stewardship. Antimicrobial resistance is one of the top human health issues globally.\"\nOndine team member, Cristina Romo, Senior Scientist and Lab Manager, was honoured as an Early Investigator's Award recipient.\n \n\n\n\n\nOndine Biomedical Inc. \n\n\n \n\n\n\n\nCarolyn Cross, CEO \n\n\n+001 (604) 665 0555\n\n\n\n\n \n\n\n \n\n\n\n\nVane Percy & Roberts (Media Contact)\n\n\n\n\n\n\n\nSimon Vane Percy, Amanda Bernard\n\n\n+44 (0)77 1000 5910\n\n\n\n\n \n...